Drugs / Hyperbaric oxygen
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02563678 | Apr 2015 → Dec 2023 | infectious disease | Intermountain Health Care, Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT00623142 | Jan 2005 → Jan 2007 | myocardial disorder | Hull University Teaching Hospitals NHS Trust | Completed | Met primary |
| Phase 27 trials · 1 missed | ||||||
| Phase 2 | NCT05173818 | Jun 2022 → Aug 2025 | traumatic encephalopathy | Essentia Health | Completed | No outcome recorded |
| Phase 2 | NCT04842448 | Sep 2021 → Sep 2023 | COVID-19, post-COVID-19 disorder | Karolinska University Hospital | Completed | Missed primary |
| Phase 2 | NCT03843671 | Jul 2019 → Dec 2022 | head and neck squamous cell carcinoma | National Baromedical Services | Unknown | No outcome recorded |
| Phase 2 | NCT03739502 | Feb 2019 → Jun 2027 expected | Hodgkins lymphoma, acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma | University of Rochester | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02407028 | Jun 2018 → Oct 2028 expected | traumatic brain injury | Gaylan Rockswold | Recruiting | No outcome recorded |
| Phase 2 | NCT01986205 | Sep 2017 → May 2022 | brain injury | Lindell Weaver | Completed | No outcome recorded |
| Phase 2 | NCT01611194 | Sep 2012 → Jan 2015 | traumatic brain injury, traumatic encephalopathy | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00989820 | Oct 2009 → May 2017 | osteoradionecrosis | Radboud University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 32 trials | ||||||
| Phase 3 | NCT06526728 | Oct 2024 → Sep 2027 expected | — | JL Tol | Recruiting | No outcome recorded |
| Phase 3 | NCT02042339 | Dec 2019 → Dec 2021 | diabetes mellitus | Medical University of Graz | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00465855 | Jun 2007 → Sep 2016 | carbon monoxide poisoning | Intermountain Health Care, Inc. | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT02025686 | Mar → Aug 2012 | — | Per Rotbøll Nielsen | Completed | No outcome recorded |
| — | NCT01430325 | Jul → Oct 2011 | traumatic brain injury | Intermountain Health Care, Inc. | Completed | No outcome recorded |
| — | NCT00087815 | Sep 2003 → Jun 2005 | central nervous system neoplasm, cognitive disorder, radiation-induced disorder | Barrett Cancer Center | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00474825 Comparator | Jul 2007 → Feb 2011 | head and neck cancer, squamous cell carcinoma | National Baromedical Services | Completed | No outcome recorded |
| Phase 2/3 | NCT01659723 Comparator | Aug 2012 → Aug 2018 | radiation cystitis | Göteborg University | Completed | No outcome recorded |
| Phase 3 | NCT05343754 Comparator | Jun 2022 → Jan 2024 | pyoderma gangrenosum | Erasmus Medical Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyperbaric Oxygen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00474825 ↗ |
| Known as | HBO2 | “The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen).” NCT01611194 ↗1“Hyperbaric oxygen (HBO2) at 1.5 ATA (active) group” NCT05173818 ↗ |
| Modality | Other / unclassified | “dose of hyperbaric oxygen therapy (HBOT)” PMID 37009524 ↗ Dec 2022 |
| Route | Other | “Patients also undergo HBOT once daily, 5 days a week, for 90 days (60 treatments total).” NCT00087815 ↗ |